JSJesse D. Sammon

Jesse D. Sammon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jesse D. Sammon has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PRState: Incorporating Genetic Ancestry in Prostate Cancer Risk scores for African American Men

    by Meghana S. Pagadala, Joshua A. Linscott, James Talwar, Tyler Seibert, Brent Rose, Julie Lynch, Matthew Panizzon, Richard Hauger, Moritz H. Hansen, Jesse D. Sammon, et al.

    Prostate cancer (PrCa) is one of the most genetically driven solid cancers with heritability estimates as high as 57%. African American men are at an increased risk of PrCa; however, current risk prediction models are based on European ancestry groups and may not be broadly applicable. In this study, we define an African ancestry group of 4,533 individuals to develop an African ancestry-specific PrCa polygenic risk score (PRState). We identified risk loci on chromosomes 3, 8, and 11 in the African ancestry group GWAS and constructed a polygenic risk score (PRS) from 10 African ancestry-specific PrCa risk SNPs, achieving an AUC of 0.61 [0.60-0.63] and 0.65 [0.64-0.67], when combined with age and family history. Performance dropped significantly when using ancestry-mismatched PRS models but remained comparable when using trans-ancestry models. Importantly, we validated the PRState score in the Million Veteran Program, demonstrating improved prediction of PrCa and metastatic PrCa in African American individuals. This study underscores the need for inclusion of individuals of African ancestry in gene variant discovery to optimize PRS.

  • National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans

    by William C. Daly, Joshua A. Linscott, Paul K. J. Han, Matthew H. Hayn, Moritz H. Hansen, Stephen T. Ryan, Scot C. Remick, Jesse D. Sammon

    Purpose:Medicaid expansion under the Affordable Care Act (ACA) occurred almost concurrently with 2012 USPSTF recommendations against PSA screening. Here the relative influence on PSA screening rate...


  • Meditative and mind-body practice among patients with genitourinary malignancy

    by William C. Daly, Paul K.J. Han, Matthew Hayn, Stephen T. Ryan, Moritz H. Hansen, Joshua P. Linscott, Quoc-Dien Trinh, Jesse D. Sammon


  • Impact of health literacy on shared decision making for prostate‐specific antigen screening in the United States

    by David‐Dan Nguyen, Quoc‐Dien Trinh, Alexander P. Cole, Kerry L. Kilbridge, Brandon A. Mahal, Matt Hayn, Moritz Hansen, Paul K. J. Han, Jesse D. Sammon

    Background: Current guidelines endorse shared decision making (SDM) for prostate‐specific antigen (PSA) screening. The relationship between a patient's health literacy (HL) and SDM remains unclear. In the current study, the authors sought to identify the impact of HL on the rates of PSA screening and on the relationship between HL and SDM following the 2012 US Preventive Services Task Force recommendations against PSA screening.Methods: Using data from the 2016 Behavioral Risk Factor Surveillance System, the authors examined PSA screening in the 13 states that administered the optional “Health Literacy” module. Men aged ≥50 years were examined. Complex samples multivariable logistic regression models were computed to assess the odds of undergoing PSA screening. The interactions between HL and SDM were also examined.Results: A weighted sample of 12.249 million men with a rate of PSA screening of 33.4% were identified. Approximately one‐third self‐identified as having optimal HL. Rates of PSA screening were found to be highest amongst the highest HL group (42.2%). Being in this group was a significant predictor of undergoing PSA screening (odds ratio, 1.214; 95% confidence interval, 1.051‐1.403). There was a significant interaction observed between HL and SDM (P for interaction, <.001) such that higher HL was associated with a lower likelihood of undergoing PSA screening when SDM was present.Conclusions: In the uncertain environment of multiple contradictory screening guidelines, men who reported higher levels of HL were found to have higher levels of screening. The authors demonstrated that increased HL may reduce the screening‐promoting effect of SDM. These findings highlight the dynamic interplay between HL and SDM that should inform the creation and promulgation of SDM guidelines, specifically when considering patients with low HL.


  • Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy

    by Joshua A. Linscott, Madeline C. Rutan, Paul K. J. Han, Moritz H. Hansen, Matthew H. Hayn, Stephen T. Ryan, Quoc-Dien Trinh, Jesse D. Sammon

    Purpose:Implementation of Survivorship Care Plans (SCP) has been emphasized as a key component to improving care for cancer survivors. Our objective was to determine the prevalence of SCP receipt f...


  • Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy

    by Jeffrey J. Leow, Eugene K. Leong, Emily C. Serrell, Steven L. Chang, Russell L. Gruen, Keng Siang Png, Lisa T. Beaule, Quoc-Dien Trinh, Mani M. Menon, Jesse D. Sammon


  • Prostate cancer navigation: initial experience and association with time to care

    by Emily C. Serrell, Moritz Hansen, Greg Mills, Andrew Perry, Tracy Robbins, Melanie Feinberg, Scot C. Remick, Lisa Beaule, Matt Hayn, Tom Kinkead, et al.

    To evaluate factors associated with use of patient navigation in a prostate cancer population and identify whether navigation is associated with prolonged time to care. Cancer patient navigation has been shown to improve access to cancer screening, diagnosis, and treatment, but little is known about patient navigation in prostate cancer care.


  • The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database

    by Alexander P. Cole, Wei Jiang, Stuart R. Lipsitz, Peter A. Learn, Maxine Sun, Toni K. Choueiri, Paul L. Nguyen, Adam S. Kibel, Mani Menon, Jesse D. Sammon, et al.

    Fee for service reimbursement incentives may affect care. We compared the odds of prostate specific antigen screening among former and active duty United States military service members based on receipt of primary care from integrated military health facilities vs community providers reimbursed via fee for service. We retrospectively studied the records of all active duty and retired male service members 40 to 64 years old who were covered by the TRICARE® military health benefit in 2010. Beneficiaries may receive primary care at military run facilities via the direct care system or with private physicians via the purchased care system. We compared rates of prostate specific antigen screening between propensity score weighted cohorts of 219,290 men who received primary care in the direct care system and 177,748 who received it in the purchased care system. The screening rate was 35% in the direct care system vs 26% in the purchased care system. After propensity score weighting the former men were significantly more likely to undergo prostate specific antigen screening than men who received primary care in the purchased care system (adjusted OR 1.76, 95% CI 1.729-1.781). Age older than 52 years, rank and black race were associated with increased odds of prostate specific antigen screening in each cohort. These results suggest that salaried primary care providers employed at integrated military facilities are more likely to order prostate specific antigen screening compared to those reimbursed in a fee for service fashion by military insurance. Growing understanding of how fee for service incentives impact prostate specific antigen screening by primary care providers may enable advocates and policy makers to leverage reimbursement systems as a tool to change prostate cancer screening.


  • Open Access

    Variation in the use of active surveillance for low‐risk prostate cancer

    by Björn Löppenberg, David F. Friedlander, Anna Krasnova, Andrew Tam, Jeffrey J. Leow, Paul L. Nguyen, Hawa Barry, Stuart R. Lipsitz, Mani Menon, Firas Abdollah, et al.

    BACKGROUND: This study assessed the use of active surveillance in men with low‐risk prostate cancer and evaluated institutional factors associated with the receipt of active surveillance.METHODS: A retrospective, hospital‐based cohort of 115,208 men with low‐risk prostate cancer diagnosed between 2010 and 2014 was used. Multivariate and mixed effects models were used to examine variation and factors associated with active surveillance.RESULTS: During the study period, the use of active surveillance increased from 6.8% in 2010 to 19.9% in 2014 (estimated annual percentage change, +28.8%; 95% confidence interval [CI], + 19.6% to + 38.7%; P = .002). The adjusted probability of active‐surveillance receipt by institution was highly variable. Compared with patients treated at comprehensive community cancer centers, patients treated at community cancer programs (odds ratio [OR], 2.00; 95% CI, 1.50‐2.67; P < .001) and academic institutions (OR, 2.47; 95%, CI, 1.81‐3.37; P < .001) had higher odds of receiving active surveillance. Compared with patients treated at very low‐volume facilities, patients treated at very high‐volume facilities had higher odds of receiving active surveillance (OR, 3.57; 95% CI, 1.94‐6.55; P < .001). Patient and hospital characteristics accounted for 60.2% of the overall variation, whereas the treating institution accounted for 91.5% of the unexplained variability.CONCLUSIONS: Within this hospital‐based cohort, the use of active surveillance for low‐risk prostate cancer increased significantly over time. Significant variation was found in the use of active surveillance. Most of the variation was attributable to facility‐related factors such as the facility type, facility volume, and institution. Policies to achieve consistent and higher rates of active surveillance, when appropriate, should be a priority of professional societies and patient advocacy groups. Cancer 2018;124:55‐64. © 2017 American Cancer Society.